A phase II trial of @entity2816 in refractory multiple @entity1582 was initiated using a dose schedule that escalated from 200 mg/d to 800 mg/d. More than two thirds of @entity1 had @entity2008 and more than half had received at least two cycles of high-dose therapy. A paraprotein reduction of at least 25% was noted in 37% of @entity1 and 14% had either a complete remission (CR) or a near CR. No treatment-related mortality was observed. With a median follow-up of almost 2 years, the 2-year event-free survival (EFS) and overall survival (OS) estimates were 15% and 60%, respectively. A reduction of paraprotein levels by greater than 50% was associated with a significant reduction in @entity236 and @entity2262 levels (beta2M), and greater recovery of hemoglobin and IgM levels compared to @entity1 whose paraprotein was reduced by a lesser degree. Responses occurred more frequently among @entity1 with a lower plasma cell labeling index (PCLI) and normal cytogenetics. Comparing response and survival by @entity2816 dose for low- and high-risk groups revealed a @entity2816 dose-response effect in the high-risk group of @entity1 . The virtual absence of @entity137 , except in heavily pretreated @entity1 with compromised bone marrow function, suggests that @entity2816 is an ideal agent to be used in combination with cytotoxic agents and @entity619 . Several trials are currently underway at the Arkansas @entity8 to determine the clinical benefit of adding @entity2816 to post-transplant salvage therapy and in the upfront management of @entity1 .

XXXX in the management of multiple @entity1582 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['Myeloma and Transplantation Research Center'] @entity137 :: ('MESH:D064420', 'Disease') :: ['myelosuppressive toxicity'] @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide'] @entity2262 :: ('567', 'Gene') :: ['beta(2)-microglobulin'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma'] @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow plasmacytosis'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['cytogenetic abnormalities']
@entity2816 :: (MESH:D013792,Chemical) :: ['Thalidomide']
